Fosun Pharma boosts subsidiaries with $102m in new guarantees

Shanghai Fosun Pharmaceutical Group has announced new guarantees for four of its controlled subsidiaries, totaling RMB 102,000 million. These guarantees include a RMB 20,000 million financing shared credit line with BNP Paribas for Fosun Pharmaceutical Industry and Fosun Antgene, and a RMB 10,000 million loan from Banco Internacional de Macau for Fosun Antgene.

Additionally, Fosun Health secured a RMB 20,000 million credit line from Shanghai Pudong Development Bank, and Fosun Yaohong (Tibet) obtained a RMB 32,000 million fixed asset loan from Bank of Tibet. These guarantees are deemed necessary and reasonable for the subsidiaries' operational needs.

As of November 6, 2025, the total external guarantees provided by the group, including the latest additions, amount to approximately RMB 2,354,378 million. This figure represents 49.82% of the group's net assets attributable to listed company shareholders as of December 31, 2024. All guarantees are inter-company transactions between the parent company and its subsidiaries or between subsidiaries themselves.

The new guarantees fall within the previously approved general guarantee limits by the company's shareholders' meeting in 2024, eliminating the need for further board or shareholder approval. Some of the guaranteed subsidiaries have a debt-to-asset ratio exceeding 70%. The company confirms no overdue guarantees as of November 6, 2025.